Novo Nordisk Reduces Sales And Operating Profit Outlook For 2025

Novo Nordisk A/S (NYSE:NVO) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to 10–16% (from 16-24%) and revenue growth projections to 8-14% (from 13-21%) at constant currency rates in its 2025 full-year guidance. The projection shows lower demand for Wegovy® and Ozempic® in the United States and a few foreign markets, despite an 18% sales and 29% profit increase in H1 2025.

The downgrading is attributed to the decreased adoption of Wegovy, resulting from continued sales of compounded GLP-1s, even after the FDA’s mass compounding grace period expired in May. The weekly prescriptions through NovoCare® Pharmacy are 11,000, with an additional 20,000 in retail cash channels. Novo Nordisk A/S (NYSE:NVO) is taking legal action and extending its telehealth and pharmaceutical collaborations. Growing competition is another factor putting pressure on Ozempic® sales in the US. Furthermore, adoption in global markets for obesity has been modest. Novo Nordisk A/S (NYSE:NVO) anticipates a DKK 3 billion net financial gain from currency hedging and DKK 35-45 billion in free cash flow. Full H1 financials will be available on August 6, 2025. It is among the Best Weight Loss Stocks.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.